Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression

PURPOSE: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) has become the first-line treatment for advanced renal cell carcinoma, despite the lack of prognostic biomarkers. Cyclin-dependent kinase 5 (CDK5) affects the tumor microenvironment, which may influence the efficacy of TKI+IO. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xianglai, Wang, Ying, Chen, Zhaoyi, Zhu, Yanjun, Wang, Jiajun, Guo, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582544/
https://www.ncbi.nlm.nih.gov/pubmed/37024096
http://dx.doi.org/10.4143/crt.2022.1532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582544/
https://www.ncbi.nlm.nih.gov/pubmed/37024096
http://dx.doi.org/10.4143/crt.2022.1532

Ejemplares similares